Lipid nanoparticle compositions comprising phospholipid derivatives and related uses
AssigneeModernaTX, Inc.
InventorsJaclyn MILTON, Mohindra SEEPERSAUD, Karthik RAMACHANDRAN, Russell B. UMSTEAD, Calvin Loishiye MARAMBO, Mark CORNEBISE
Life of this patent
Estimating the term…
Abstract
The present disclosure provides lipid assemblies suitable for delivery of therapeutic agents to hematopoietic stem and progenitor cells (HSPCs), wherein the lipid assemblies comprise a phosphatidylserine phospholipid. The present disclosure also provides therapeutic and diagnostic uses related to the lipid assemblies.
Claims33
A lipid assembly comprising a phosphatidylserine phospholipid, an ionizable lipid, and a structural lipid, wherein the phosphatidylserine phospholipid is of Formula (PL-I):
- or a salt thereof, wherein:
- n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
- m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
- A is of the formula:
- each instance of L2 is independently a bond or an optionally substituted C1-6 alkylene, wherein one methylene unit of the optionally substituted C1-6 alkylene is optionally replaced with —O—, —N(RN)—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(RN)—, —NRNC(O)O—, or —NRNC(O)N(RN)—;
- each instance of R2 is independently cholesterol, optionally substituted cycloalkyl, optionally substituted C1-30 alkyl, optionally substituted C1-30 alkenyl, or optionally substituted C1-30 alkynyl;
- optionally wherein one or more methylene units of the optionally substituted C1-30 alkyl, optionally substituted C1-30 alkenyl, or optionally substituted C1-30 alkynyl are independently replaced with optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, —N(RN)—, —O—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —NRNC(O)N(RN)—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(RN)—, —NRNC(O)O—, —C(O)S—, —SC(O)—, —C(═NRN)—, —C(═NRN)N(RN)—, —NRNC(═NRN)—, —NRNC(═NRN)N(RN)—, —C(S)—, —C(S)N(RN)—, —NRNC(S)—, —NRNC(S)N(RN)—, —S(O)—, —OS(O)—, —S(O)O—, —OS(O)O—, —OS(O)2—, —S(O)2O—, —OS(O)2O—, —N(RN)S(O)—, —S(O)N(RN)—, —N(RN)S(O)N(RN)—, —OS(O)N(RN)—, —N(RN)S(O)O—, —S(O)2—, —N(RN)S(O)2—, —S(O)2N(RN)—, —N(RN)S(O)2N(RN)—, —OS(O)2N(RN)—, or —N(RN)S(O)2O—;
- each instance of RN is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group;
- Ring B is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
- and
- p is 1 or 2.
A population of lipid assemblies comprising a phosphatidylserine phospholipid, an ionizable lipid, and a structural lipid, wherein the phosphatidylserine phospholipid is of Formula (PL-I):
- or a salt thereof, wherein:
- n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
- m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
- A is of the formula:
- each instance of L2 is independently a bond or an optionally substituted C1-6 alkylene, wherein one methylene unit of the optionally substituted C1-6 alkylene is optionally replaced with —O—, —N(RN)—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(RN)—, —NRNC(O)O—, or —NRNC(O)N(RN)—;
- each instance of R2 is independently cholesterol, optionally substituted cycloalkyl, optionally substituted C1-30 alkyl, optionally substituted C1-30 alkenyl, or optionally substituted C1-30 alkynyl;
- optionally wherein one or more methylene units of the optionally substituted C1-30 alkyl, optionally substituted C1-30 alkenyl, or optionally substituted C1-30 alkynyl are independently replaced with optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, —N(RN)—, —O—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —NRNC(O)N(RN)—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(RN)—, —NRNC(O)O—, —C(O)S—, —SC(O)—, —C(═NRN)—, —C(═NRN)N(RN)—, —NRNC(═NRN)—, —NRNC(═NRN)N(RN)—, —C(S)—, —C(S)N(RN)—, —NRNC(S)—, —NRNC(S)N(RN)—, —S(O)—, —OS(O)—, —S(O)O—, —OS(O)O—, —OS(O)2—, —S(O)2O—, —OS(O)2O—, —N(RN)S(O)—, —S(O)N(RN)—, —N(RN)S(O)N(RN)—, —OS(O)N(RN)—, —N(RN)S(O)O—, —S(O)2—, —N(RN)S(O)2—, —S(O)2N(RN)—, —N(RN)S(O)2N(RN)—, —OS(O)2N(RN)—, or —N(RN)S(O)2O—;
- each instance of RN is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group;
- Ring B is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
- and
- p is 1 or 2.
The lipid assembly or the population of lipid assemblies of any one of the preceding claims, wherein the phosphatidylserine phospholipid is of Formula (PL-Ib):
- or a salt thereof.
The lipid assembly or the population of lipid assemblies of any one of the preceding claims, wherein each instance of R2 is independently C1-30, C9-21, C11-19, or C13-17 alkyl or C1-30, C9-21, C11-19, or C13-17 alkenyl.
The lipid assembly or the population of lipid assemblies of any one of the preceding claims, wherein the phosphatidylserine phospholipid is
- or a salt thereof.
The lipid assembly or the population of lipid assemblies of any one of the preceding claims, comprising between about 1 mol % to about 10 mol %, about 1 mol % to about 8 mol %, about 1 mol % to about 5 mol %, or about 2 mol % to about 5 mol % of the phosphatidylserine phospholipid;
- and/or
- comprising about 1 mol %, about 2 mol %, about 3 mol %, about 4 mol %, or about 5 mol % of the phosphatidylserine phospholipid.
The lipid assembly or the population of lipid assemblies of any one of the preceding claims, comprising about 30 mol % to about 50 mol %, about 30 mol % to about 45 mol %, about 30 mol % to about 40 mol %, about 35 mol % to about 45 mol %, or about 35 mol % to about 40 mol % of the ionizable lipid;
- and/or
- comprising about 30 mol %, about 35 mol %, about 40 mol %, about 45 mol %, or about 50 mol % of the ionizable lipid;
- and/or
- wherein the ionizable lipid is compound 301 or compound 22.
The lipid assembly or the population of lipid assemblies of any one of the preceding claims, comprising about 15 mol % to about 45 mol %, about 20 mol % to about 45 mol %, about 25 mol % to about 45 mol %, about 30 mol % to about 45 mol %, about 35 mol % to about 45 mol %, or about 40 mol % to about 45 mol % of the structural lipid;
- and/or
- comprising about 15 mol %, about 20 mol %, about 25 mol %, about 30 mol %, about 35 mol %, about 40 mol %, or about 45 mol % of the structural lipid;
- and/or
- wherein the structural lipid is cholesterol.
The lipid assembly or the population of lipid assemblies of any one of the preceding claims, further comprising a second phospholipid;
- optionally:
- comprising about 10 mol % to about 30 mol %, 10 mol % to about 25 mol %, 10 mol % to about 20 mol %, about 15 mol % to about 25 mol %, or about 15 mol % to about 20 mol % of the second phospholipid;
- and/or:
- comprising about 10 mol %, about 15 mol %, about 18 mol %, about 20 mol %, about 22 mol %, about 25 mol %, or about 30 mol % of the second phospholipid;
- and/or
- wherein the second phospholipid is DSPC, DOPE, DOPC, POPE, or POPC.
The lipid assembly or the population of lipid assemblies of any one of the preceding claims, being free of PEG lipid.
The lipid assembly or the population of lipid assemblies of any one of the preceding claims, having a pH value lower than the pKa value of the ionizable lipid;
- and/or
- having a pH value of about 4.0±2.0, about 4.0±1.5, about 4.0±1.4, about 4.0±1.3, about 4.0±1.2, about 4.0±1.1, about 4.0±1.0, about 4.0±0.9, about 4.0±0.8, about 4.0±0.7, about 4.0±0.6, about 4.0±0.5, about 4.0±0.4, about 4.0±0.3, about 4.0±0.2, or about 4.0±0.1;
- or
- having a pH value of about 5.0±2.0, about 5.0±1.5, about 5.0±1.4, about 5.0±1.3, about 5.0±1.2, about 5.0±1.1, about 5.0±1.0, about 5.0±0.9, about 5.0±0.8, about 5.0±0.7, about 5.0±0.6, about 5.0±0.5, about 5.0±0.4, about 5.0±0.3, about 5.0±0.2, or about 5.0±0.1.
The lipid assembly or the population of lipid assemblies of any preceding claim, having a zeta potential between about −40 mV to about −5 mV, about −30 mV to about −5 mV, about −20 mV to about −5 mV, about −40 mV to about −10 mV, about −30 mV to about −10 mv, or about −20 mV to about −10 mV when measured in 0.1N PBS at pH 7.5.
The lipid assembly or the population of lipid assemblies of any one of the preceding claims, being free of therapeutic agent.
A process of preparing a nanoparticle, the process comprising contacting an aqueous stream comprising a phosphatidylserine lipid with an organic stream comprising an ionizable lipid and a structural lipid, thereby obtaining a mixed product;
- optionally:
- wherein the organic stream further comprises a PEG lipid;
- and/or
- wherein the pH of the aqueous stream is lower than the pKa of the ionizable lipid.
Dependencies are inferred from the claim text.